Pharmaceutical - Actos, Diabetes


Current filters:


Popular Filters

Jury finds in favor of Takeda in diabetes drug Actos case


The US subsidiary of Japan’s largest drugmaker, Takeda Pharmaceuticals, yesterday announced that in…

ActosDiabetesLegalPharmaceuticalTakeda PharmaceuticalsUSA

Takeda ordered to pay $6 billion damages in Actos trial

Takeda ordered to pay $6 billion damages in Actos trial


Japan’s largest drugmaker Takeda Pharmaceutical has been ordered to pay $6 billion in punitive damages…

ActosDiabetesEli Lilly and CompanyJapanJudgeLegalMajorPharmaceuticalPyridinesTakeda NycomedThiazolidinedionesUSA

US Judge throws out verdict in Takeda Actos case


The US subsidiary of Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) USA announced that,…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

Takeda considering options over US Actos court ruling


The US subsidiary of Japan's largest drugmaker, Takeda Pharmaceuticals (TYO 4502), says that in the case…

ActosDiabetesLegalNorth AmericaPharmaceuticalTakeda Pharmaceuticals

US FDA again delays action on Takeda's alogliptin diabetes drug


Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it has received a complete response…

ActosalogliptinDiabetesNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

EC backs continued use of pioglitazone drugs for diabetes


Japan’s largest drugmaker, Takeda Pharmaceutical (TYO 4502) said yesterday that the European Commission…

ActosDiabetesEuropePharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Takeda ends Daxas co-promotion with MSD; Actos law suits


Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Prior CHMP positive benefit-risk for pioglitazone confirmed; EMA starts NSAIDS review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has clarified its…

ActosDiabetesEuropeNeurologicalPharmaceuticalPioglitazoneRegulationTakeda Pharmaceuticals

Back to top